Norepinephrine Fuels Microglial Migration March 19, 2010 New evidence suggests that endogenous neurotransmitters may play a critical role in controlling glial activation and microglial migration. This news update in Alzforum raises the possibility that centrally acting noradrenergic modulators may be beneficial in an ALS context. Has anyone ever looked?
Return of the Small Family Study? Whole-Genome Analysis Shows Power March 12, 2010 Two new papers use whole-genome sequencing within a single family to identify disease genes for rare heritable conditions. As the cost of such efforts decreases, this approach may provide new genetic insights into ALS.
Dimebon Disappoints in Phase 3 Trial March 4, 2010 Medivation has reported that the company's experimental Alzheimer's drug Dimebon failed in a Phase 3 trial. Though it failed the Alzheimer's trial, the drug is still being investigated for Huntington's disease, and given its purported mechanism of action, Dimebon also has therapeutic implications for ALS.
Research News has been provided in partnership with alzforum.org
